Chromosome 17q23.1-q23.2 deletion syndrome is a very rare genetic condition. In this syndrome, a tiny piece of DNA is missing from the long arm (q arm) of chromosome 17, between bands q23.1 and q23.2. This missing piece is called a “microdeletion. The deleted region usually includes important genes such as TBX2 and TBX4. These genes help guide the early growth of the heart, lungs, bones, hands, feet, and other body parts. When one copy of these genes is missing (haploinsufficiency), body systems may not form in the usual way.
Chromosome 17q23.1-q23.2 deletion syndrome (also called 17q23.1q23.2 microdeletion syndrome) is an ultra-rare genetic condition where a small piece of chromosome 17 is missing. This region usually includes the TBX2 and TBX4 genes, which are important for normal development of the brain, heart, lungs, and limbs.[]
Because different genes can be lost in different people, the symptoms vary, but often include developmental delay, speech delay, microcephaly, short stature, congenital heart defects, limb and patella abnormalities, scoliosis, pulmonary arterial hypertension (PAH), and hearing loss.[]
There is no cure or single “targeted” drug for this microdeletion; treatment is supportive and symptom-based, ideally led by a multidisciplinary team (clinical genetics, cardiology, pulmonology, neurology, orthopedics, rehab, nutrition, and psychology).[]
People with this syndrome often have developmental delay, microcephaly (a small head size), short height, congenital heart defects, and limb or skeletal abnormalities like differences in hands, feet, legs, or hips. Many also have speech delay, learning problems, and sometimes distinctive facial features.
Other Names and Types
This condition has several other names used in the medical literature. All of them describe the same or very closely related microdeletion region on chromosome 17:
-
17q23.1q23.2 microdeletion syndrome
-
del(17)(q23.1q23.2)
-
Monosomy 17q23.1q23.2
-
Chromosome 17q23.1-q23.2 deletion syndrome
-
17q23.1q23.2 recurrent microdeletion (includes TBX2, TBX4)
Doctors sometimes also talk about types or patterns of the deletion. These are not “different diseases,” but different sizes or shapes of the missing DNA:
-
Typical recurrent ~2.2 Mb deletion including TBX2 and TBX4
-
Smaller “atypical” deletions that only include part of the usual region
-
Larger deletions that extend beyond q23.1-q23.2 into nearby bands
-
Deletions that happen alone (isolated microdeletion)
-
Deletions that occur as part of a more complex chromosome change (for example with other gains or losses)
-
Deletions that are de novo (new in the child)
-
Deletions that are inherited from a parent who carries a balanced chromosome rearrangement
These patterns can partly explain why some children have more severe features and others have milder features, even though the name of the syndrome is the same.
Causes
In simple words, the cause is loss of a small piece of chromosome 17 at 17q23.1-q23.2. But there are many ways this loss can happen. Most are random and not due to anything the parents did or did not do.
1. Recurrent microdeletion at 17q23.1-q23.2
The main cause is a small missing section of DNA between bands q23.1 and q23.2 on chromosome 17. This deletion tends to have similar size and breakpoints in many patients, so it is called a recurrent microdeletion.
2. Loss of TBX2 and TBX4 genes (haploinsufficiency)
Most typical deletions remove one copy of the TBX2 and TBX4 genes. With only one working copy instead of two, the body does not get enough of these proteins. This shortage (haploinsufficiency) disturbs normal development of the heart, lungs, limbs, and skeleton.
3. De novo (new) chromosome error in the child
In many families, neither parent has the deletion. The microdeletion appears de novo, meaning it happens for the first time in the egg or sperm or very early after fertilization. This is a random genetic event and cannot be predicted before it happens.
4. Non-allelic homologous recombination (NAHR)
Many recurrent microdeletions in the genome, including 17q23.1-q23.2, are caused by NAHR, a mistake during the exchange of DNA between chromosomes in egg or sperm formation. Similar repeated DNA blocks (low-copy repeats) can misalign, so crossing-over removes the segment between them.
5. Flanking segmental duplications (low-copy repeats)
The 17q23.1-q23.2 region is bordered by highly similar repeated DNA pieces called segmental duplications or low-copy repeats. These repeats make the region unstable and more likely to undergo NAHR, leading to recurrent deletions.
6. Unbalanced segregation of a parental balanced rearrangement
In some cases, a parent has a balanced translocation or inversion involving chromosome 17. The parent is usually healthy because no DNA is lost. But when chromosomes are passed to the child, the balance can be broken, leading to an unbalanced state with a 17q23.1-q23.2 deletion in the child.
7. Complex chromosomal rearrangements
Very rarely, a child may have a complex structural change with several deletions and duplications, one of which includes 17q23.1-q23.2. The overall picture then combines features of several affected regions.
8. Parental germline mosaicism
Sometimes the deletion is present only in a small number of a parent’s egg or sperm cells (germline mosaicism). The parent’s blood test appears normal, but the change can still be passed on to one or more children. This is known from other microdeletion syndromes and may also occur in this region.
9. Unequal crossing-over (a type of NAHR)
Unequal crossing-over is another way to describe the same idea: when homologous chromosomes line up, they may not match perfectly, so crossing-over cuts out more DNA from one chromosome and adds extra DNA to the other. The “short” chromosome carries the 17q23.1-q23.2 deletion.
10. General genomic instability in repeat-rich regions
Regions with many repeats and structural variants are more prone to breaks and rearrangements. The 17q23 area is one such region. Over many generations, this instability increases the chance that some embryos will carry a deletion.
11. Very rare inheritance of the same microdeletion
In a small number of families, the same 17q23.1-q23.2 microdeletion may be inherited from an affected or mildly affected parent. In these families, the deletion behaves like a dominant genetic trait, with variable severity.
12. Haploinsufficiency for other genes in the region
Besides TBX2 and TBX4, several other genes in the deleted segment may contribute to the full syndrome. Losing one copy of multiple genes at once can affect brain development, growth, hearing, and skeletal formation.
13. Interaction with other copy-number variants
Some patients have the 17q23.1-q23.2 deletion plus other copy-number changes on different chromosomes. These extra changes may modify the severity of developmental delay, learning problems, or physical anomalies.
14. Very low birth weight and growth restriction linked to deletion
In reported newborn cases, severe intrauterine growth restriction and poor postnatal growth are common, suggesting that the deletion itself interferes with growth pathways before and after birth.
15. Disturbed heart-development pathways
Because TBX genes regulate early heart patterning, their loss disrupts normal heart tube and valve formation. This explains why congenital heart defects are a core feature of the syndrome.
16. Disturbed limb and skeletal-development pathways
TBX4 especially is important for hind-limb and pelvic development. Deletion of this gene is linked to limb malformations, small patella syndrome, and sometimes pulmonary arterial hypertension, which together shape the limb-skeletal pattern in this condition.
17. Brain-development effects leading to microcephaly
Microcephaly and developmental delay suggest that genes inside the deleted region also help guide brain growth. When they are missing, brain size and connections may be reduced, causing small head size and learning difficulties.
18. Possible influence of parental age (general chromosomal risk)
For many chromosomal disorders, increased parental age slightly raises the risk of errors during egg or sperm formation. This pattern is known at a general level but has not been clearly proven specifically for this rare syndrome.
19. Environmental factors that damage DNA (general background)
Strong radiation or some toxic chemicals can damage DNA in germ cells, which might, in theory, contribute to new chromosomal rearrangements. However, for 17q23.1-q23.2 deletion syndrome, no specific environmental cause has been clearly shown; most cases remain random.
20. Chance (stochastic) events in early cell division
Even after fertilization, early cell divisions can sometimes mis-repair chromosome breaks and create a deletion in some or all cells of the embryo. These chance events are part of why many rare microdeletions are sporadic and unpredictable.
Symptoms
Not every person has the same symptoms, and severity can vary a lot, even in the same family. But some features are seen again and again in published case reports and summaries.
1. Developmental delay
Many children learn to sit, crawl, walk, and talk later than their peers. The delay can be mild to moderate, and school learning may also be slower. Early intervention and special education support can greatly help.
2. Intellectual disability or learning difficulties
Some individuals have mild to moderate intellectual disability. Others may have a normal IQ but still struggle with specific learning skills, attention, or processing speed.
3. Speech and language delay
Speech delay is a very common feature. Children may start using single words late, have trouble putting words into sentences, or have ongoing expressive language problems while understanding more than they can say.
4. Microcephaly (small head size)
Many patients have a head circumference smaller than expected for age and sex. Microcephaly reflects differences in brain growth and is one of the classic signs mentioned in most descriptions of the syndrome.
5. Short stature and poor growth
Children often have low birth weight, grow slowly in infancy, and remain shorter than average. Some have poor weight gain (failure to thrive), especially in early life.
6. Congenital heart defects
A variety of structural heart problems can occur, such as atrial or ventricular septal defects or patent ductus arteriosus. These defects may cause heart murmurs, poor feeding, fast breathing, or tiredness.
7. Limb and hand-foot abnormalities
Some individuals have differences in their hands or feet, such as short fingers or toes, curved fingers, abnormal nails, or limb length differences. These changes may affect walking, running, or fine motor skills.
8. Skeletal abnormalities
Problems like small patellae (kneecaps), hip dysplasia, spinal curvature (scoliosis), or chest wall differences can be present. These skeletal issues may lead to joint pain, gait problems, or need for orthopedic follow-up.
9. Distinctive facial features
Some patients share subtle facial traits such as a small jaw (micrognathia), small mouth, high-arched palate, or asymmetric face. These features are often mild and do not define the person but help geneticists recognize the syndrome.
10. Low muscle tone (hypotonia)
Infants may feel “floppy” when held, with weak muscle tone. Hypotonia can make feeding, rolling, sitting, and walking more difficult and may lead to delayed motor milestones.
11. Feeding and swallowing difficulties
Poor sucking, difficulty coordinating swallowing, or reflux are common in early life. Some babies need feeding therapy, thickened feeds, or temporary support such as a feeding tube.
12. Hearing loss or recurrent ear problems
Some individuals have conductive or sensorineural hearing loss, or frequent ear infections. Hearing issues can further affect speech and language development if not identified early.
13. Respiratory or pulmonary problems
Because TBX4 is linked to lung and pulmonary artery development, some patients may have breathing problems or pulmonary arterial hypertension. These issues need careful cardiology and respiratory follow-up.
14. Seizures (in some patients)
Seizures are not present in everyone but have been reported in some cases. When present, they may be associated with developmental delay and need evaluation by a neurologist.
15. Behavioral or emotional difficulties
Some children may have attention problems, hyperactivity, anxiety, or autistic-like features. These behaviors vary widely and often improve with tailored therapies, structure, and support.
Diagnostic Tests
Diagnosis usually begins with noticing growth problems, developmental delay, or unusual physical features, and then confirming the chromosome change with genetic tests. Many other tests are used to check body systems and guide care.
Physical exam tests
1. Complete pediatric physical examination
A detailed head-to-toe exam looks at growth, head size, facial shape, chest, heart sounds, abdomen, limbs, skin, and genital area. The doctor notes any features that may point to a syndrome and records them carefully.
2. Growth chart and head-circumference measurement
Height, weight, and head size are plotted on standardized charts. Falling below expected curves or crossing percentiles downward helps identify short stature and microcephaly, which are key features of this syndrome.
3. Cardiovascular examination
The doctor listens to the heart with a stethoscope, checking for murmurs, extra sounds, or abnormal rhythms. Pulse quality, blood pressure, and signs of heart failure (like swelling or rapid breathing) are also evaluated.
4. Musculoskeletal and limb examination
Hands, feet, arms, legs, hips, and spine are examined for shape, joint range of motion, limb length differences, and patella size. This helps reveal limb and skeletal abnormalities linked to the 17q23.1-q23.2 deletion.
Manual / bedside functional tests
5. Developmental screening tests
Simple tools such as checklists or play-based tasks are used to see how the child is doing in motor skills, language, social skills, and problem-solving. These tests help decide whether more formal developmental or psychological testing is needed.
6. Neurological bedside examination
The clinician checks muscle tone, reflexes, strength, coordination, and eye movements. This exam helps identify hypotonia, asymmetry, or other neurological signs that go along with developmental delay or seizures.
7. Hearing screening (bedside or simple audiology tests)
Basic hearing checks (such as response to sounds, simple audiometry, or otoacoustic emissions) are used to detect early hearing problems. If screening is abnormal, more detailed hearing tests are arranged.
8. Feeding and swallowing assessment
A speech-language or feeding therapist observes how the child sucks, chews, and swallows different textures. This “manual” assessment helps to plan safe feeding methods and identify the need for further imaging.
Laboratory and pathological tests
9. Chromosomal microarray (CMA)
CMA is the key test to confirm chromosome 17q23.1-q23.2 deletion syndrome. It scans the whole genome for extra or missing pieces of DNA and can precisely identify the size and position of the 17q23.1-q23.2 microdeletion.
10. Targeted FISH testing for 17q23.1-q23.2
Fluorescence in situ hybridization (FISH) uses fluorescent DNA probes that bind to the 17q23.1-q23.2 region. If the probe signal is missing on one chromosome 17, it confirms the deletion and can also be used to test parents.
11. Conventional karyotype
A standard chromosome picture (karyotype) can sometimes show larger deletions or balanced translocations involving chromosome 17. It is less sensitive than CMA but helpful to detect parental balanced rearrangements.
12. MLPA or other copy-number assays for TBX2/TBX4
Multiplex ligation-dependent probe amplification (MLPA) and similar tests can measure copy number of specific genes like TBX2 and TBX4. Reduced signal suggests a deletion affecting these critical genes.
13. Whole-exome or genome sequencing
If CMA is normal but suspicion remains high, exome or genome sequencing can look for smaller deletions or changes in single genes that might mimic the syndrome. It can also detect additional variants that modify the clinical picture.
14. Basic blood tests (CBC, chemistry panel)
Complete blood count and basic chemistry tests check general health, anemia, infection, or organ function. These tests are not specific for the syndrome but help guide safe treatment and anesthesia for surgeries.
15. Endocrine and metabolic screening (when indicated)
If growth failure is severe, doctors may test thyroid function, blood sugar, and other hormones or metabolic markers. These tests rule out additional treatable conditions that might worsen growth or development.
Electrodiagnostic tests
16. Electroencephalogram (EEG)
If seizures or unusual spells are suspected, an EEG records the brain’s electrical activity. Abnormal wave patterns can confirm epilepsy and help choose the right anti-seizure medicine.
17. Nerve conduction studies / EMG (in selected cases)
If there is significant hypotonia, weakness, or unusual limb findings, nerve conduction studies and electromyography (EMG) may be done to check nerve and muscle function, although they are not routine for every patient with this deletion.
Imaging tests
18. Echocardiogram (heart ultrasound)
An echocardiogram uses sound waves to create pictures of the heart’s structure and function. It is essential to detect or follow congenital heart defects that are common in this syndrome.
19. Skeletal X-rays and orthopedic imaging
X-rays of the spine, hips, knees, hands, or feet can show small patellae, hip dysplasia, scoliosis, or other bone changes. These images guide decisions about physical therapy, braces, or surgery.
20. Brain MRI (when indicated)
If there are seizures, severe developmental delay, or unusual neurological signs, brain MRI can look for structural differences such as reduced brain volume or other anomalies that may be related to the microdeletion.
Non-pharmacological (non-drug) treatments and therapies
Because Chromosome 17q23.1-q23.2 deletion syndrome affects many body systems, non-pharmacological care is the foundation of long-term management. Each therapy below is general and must be tailored to the specific child or adult.
1. Early developmental intervention and physiotherapy
Early intervention programs provide structured play-based activities to support motor, language, and cognitive skills from infancy. The purpose is to reduce the impact of global developmental delay and low muscle tone, which are common in this microdeletion.[]
Physiotherapists use stretching, strengthening, and balance exercises to improve sitting, walking, posture, and muscle strength. The mechanism is neuroplasticity: repeated practice helps the brain form more efficient movement patterns, compensating for underlying structural and tone abnormalities.
2. Occupational therapy (OT)
Occupational therapists focus on daily living skills such as feeding, dressing, handwriting, and fine motor control in children with long thin fingers, joint stiffness, or patella problems.[]
The purpose is to maximise independence and participation at home and in school. Techniques include task-specific training, adapted grips, splints, and environmental modifications. Mechanistically, OT reduces functional limitation by breaking complex tasks into manageable steps and optimising joint alignment and muscle use.
3. Speech and language therapy
Speech delay and language impairment are frequent features of 17q23.1q23.2 microdeletion syndrome.[]
Speech therapists assess understanding, expression, and speech clarity, and then provide exercises, picture systems, or communication devices. The purpose is to improve communication, behaviour, and social interaction. The mechanism is repetitive language practice, modelling, and feedback, which strengthens the neural pathways for speech and language processing.
4. Special education and individualized educational plans (IEP)
Mild to moderate intellectual or learning difficulties are reported in many but not all patients.[]
Special education services adapt teaching speed, materials, and classroom support. The purpose is to allow the child to learn at their own pace while staying included with peers. The mechanism is educational scaffolding—breaking tasks into smaller steps, using visual aids, repetition, and multi-sensory teaching.
5. Cardiac rehabilitation and activity guidance
Congenital heart defects (such as patent ductus arteriosus and atrial septal defects) and pulmonary arterial hypertension can limit exercise capacity.[]
Cardiac rehab teams teach safe levels of activity, breathing techniques, and energy conservation. The purpose is to improve fitness and quality of life without over-straining the heart and lungs. Mechanistically, carefully graded aerobic exercise improves oxygen use, muscle strength, and mood.
6. Orthopedic and physiotherapy management of skeletal problems
This syndrome can cause patellar hypoplasia, joint contractures, scoliosis, flat feet, and limb abnormalities.[]
Non-surgical management includes braces, orthotics, stretching, and posture training. The purpose is to maintain joint mobility, reduce pain, and delay or even avoid surgery. The mechanism is mechanical: external supports correct alignment, while exercises keep muscles and ligaments flexible and strong.
7. Hearing rehabilitation and communication support
Sensorineural hearing impairment is reported in some patients with deletions involving TBX2/TBX4.[]
Audiology care may involve hearing aids, bone-anchored devices, or cochlear implants, combined with language therapy. The purpose is to ensure the child has access to sound for speech, learning, and socialising. The mechanism is amplification or direct stimulation of the auditory pathway to bypass damaged structures.
8. Feeding, nutrition, and reflux management (non-drug)
Feeding difficulties, poor weight gain, and gastro-oesophageal reflux are common in many chromosomal microdeletion syndromes and are listed among possible symptoms here.[]
Non-drug strategies include thickened feeds, upright positioning, smaller/more frequent feeds, and specialist feeding therapy. The purpose is to improve calorie intake, reduce vomiting, and prevent aspiration. Mechanistically, posture and texture changes reduce reflux and make swallowing safer.
9. Respiratory and PAH-focused physiotherapy
When pulmonary arterial hypertension or chronic lung issues are present, respiratory physiotherapists teach breathing exercises, airway clearance, and pacing.[]
The purpose is to maintain lung function, reduce breathlessness, and support participation in daily activities. Mechanistically, breathing techniques optimise ventilation–perfusion matching and reduce dynamic airway collapse.
10. Psychological support and family counselling
Caring for a child with a very rare genetic syndrome is emotionally and practically demanding. Families may feel isolated, especially since only a small number of cases are described worldwide.[]
Psychological support helps parents cope with uncertainty, grief, and stress, and can address behavioural or emotional difficulties in the child. The mechanism is a mix of cognitive-behavioural strategies, problem-solving, and supportive counselling to build resilience.
Drug treatments
There is no medicine that “fixes” the missing 17q23.1-q23.2 region. Drug treatment targets specific complications such as pulmonary arterial hypertension, congenital heart disease, seizures, reflux, or infections.[]
All medications must be prescribed and monitored by specialists; dosing here is illustrative and must never be used for self-treatment.
1. Endothelin-receptor antagonists (bosentan, ambrisentan)
PAH is strongly linked to TBX4-related disease and has been reported in people with this microdeletion.[]
Bosentan (Tracleer) is an endothelin-receptor antagonist indicated for WHO Group 1 PAH to improve exercise ability and reduce clinical worsening.[]
Ambrisentan (Letairis) is another oral endothelin-receptor antagonist approved for PAH to improve exercise capacity and delay clinical worsening, sometimes combined with tadalafil.[]
These drugs block endothelin-1, a potent vasoconstrictor, leading to vasodilation in the pulmonary circulation, but can cause liver toxicity, edema, anaemia, and birth defects.
2. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)
Sildenafil (Revatio) is a PDE-5 inhibitor approved for PAH in adults and, more recently, in children 1–17 years to improve exercise capacity and pulmonary haemodynamics.[]
It increases cyclic GMP in smooth muscle, causing vasodilation of pulmonary vessels. Labelled adult doses are usually 20 mg three times daily, but paediatric regimens are specialist-determined.[]
Side effects can include headache, flushing, hypotension, visual symptoms, and rare serious cardiovascular events. Tadalafil has a similar mechanism with longer action.
3. Prostacyclin pathway drugs (epoprostenol, treprostinil)
Epoprostenol (Flolan) is an intravenous prostacyclin analogue indicated for WHO Group 1 PAH to improve exercise capacity, especially in severe (NYHA class III–IV) disease.[]
It acts by vasodilation and inhibition of platelet aggregation in pulmonary arteries. Continuous IV infusion can markedly improve symptoms but carries risks of line infection, hypotension, and rebound PAH if abruptly stopped. Treprostinil (Remodulin) is a related prostacyclin analogue that can be given subcutaneously, intravenously, or by inhalation.[]
4. Combination PAH therapy (dual or triple)
Case series of TBX4-related PAH and pediatric PAH describe combinations such as bosentan plus sildenafil, or ambrisentan plus tadalafil, guided by international PAH guidelines.[]
The purpose is to target several pathways (endothelin, nitric oxide–cGMP, prostacyclin) to better control pulmonary pressures and improve functional class. The mechanism is additive vasodilation and anti-remodelling, but side effects and monitoring burden increase.
5. Heart-failure and congenital heart disease drugs
Many children with 17q23.1-q23.2 deletion have structural heart defects such as atrial septal defect or persistent ductus arteriosus, sometimes with heart failure.[]
Cardiologists may use diuretics (e.g., furosemide), ACE inhibitors (e.g., enalapril), or beta-blockers to control fluid overload and ventricular function. The purpose is to reduce symptoms like breathlessness and poor feeding while awaiting growth or surgery. Mechanistically, these drugs lower preload/afterload and improve cardiac efficiency but can cause electrolyte abnormalities, low blood pressure, or kidney effects.
6. Antiseizure medications (if epilepsy is present)
Some individuals with microdeletion syndromes develop seizures, although this is not universal.[]
Neurologists may prescribe antiseizure drugs such as levetiracetam, valproate, or others, based on seizure type and EEG findings. These medicines stabilise neuronal excitability by modulating ion channels or neurotransmitters, reducing seizure frequency. Side effects can include behavioural changes, liver toxicity, or blood abnormalities, so monitoring is essential.
7. Gastro-oesophageal reflux and feeding medications
For significant reflux and feeding difficulties, doctors may add acid-suppressing drugs (proton pump inhibitors like omeprazole) or prokinetic agents after non-drug strategies.[]
These reduce acid exposure and speed gastric emptying, helping weight gain and decreasing aspiration risk. However, long-term PPI use can increase risk of infections and nutrient malabsorption, so they are used at the lowest effective dose.
8. Analgesics and musculoskeletal symptom relief
Pain from joint contractures, scoliosis, or orthopedic surgery may require paracetamol or carefully supervised non-steroidal anti-inflammatory drugs. The purpose is to allow participation in physiotherapy and daily activities. These drugs work by blocking prostaglandin pathways but can affect kidneys, stomach, and platelets, especially in children with complex heart or lung disease.
9. Vaccinations and infection management
Although not disease-specific “drugs,” standard and sometimes expanded vaccinations (e.g., influenza, pneumococcal, RSV prevention where available) are important in a child with cardiac or pulmonary involvement.[]
Prompt antibiotics may be needed for ear infections or pneumonia, particularly where hearing impairment or chronic otitis media exist. The mechanism is simply preventing or treating infections that can dramatically worsen cardiopulmonary function.
10. Behavioural and psychiatric medications (if needed)
Some individuals have behavioural difficulties, anxiety, or attention problems.[]
Child psychiatrists may rarely use medications like stimulants, SSRIs, or atypical antipsychotics in addition to behavioural therapy. These drugs adjust neurotransmitter levels to improve mood, attention, or aggression, but must be used cautiously because of possible effects on appetite, growth, and heart rhythm.
Dietary molecular supplements (supportive, not curative)
There are no supplements proven to treat the microdeletion itself. Any use is supportive and should be supervised by a clinician or dietitian, especially in children with heart or lung disease. Evidence is usually extrapolated from general paediatric or PAH populations rather than this exact syndrome.[]
Examples often discussed in practice (always individualized):
-
Vitamin D and calcium – important for bone health, particularly if mobility is limited or long-term steroids are used. They support bone mineralisation and muscle function but can cause toxicity if overdosed.
-
Omega-3 fatty acids – may modestly support cardiovascular health and reduce inflammation, potentially helpful in children with congenital heart disease, though data are general and not syndrome-specific.
-
Multivitamin with iron – useful where diet is limited or there is chronic illness and poor intake; supports red blood cell production and immune function.
-
Coenzyme Q10 – sometimes used in chronic cardiac or muscular conditions; it supports mitochondrial energy production but evidence in children is limited.
-
L-carnitine – may be considered when muscle weakness is prominent or in specific metabolic disorders; it helps transport fatty acids into mitochondria for energy.
Because this condition is rare and complex, supplements should never replace standard medical and nutritional care.
Immune-booster, regenerative and stem-cell drugs
At present, there are no approved immune-boosting, regenerative, or stem-cell drugs specifically for Chromosome 17q23.1-q23.2 deletion syndrome.
Published reports and expert resources emphasise symptomatic and supportive care; stem-cell or gene-therapy approaches remain experimental and, if used at all, would only occur within controlled clinical trials.[]
Families should be cautious about clinics advertising “stem cell cures” without strong scientific evidence or regulatory oversight.
Surgical options
Surgery is considered when structural problems significantly affect function or survival.
1. Repair of congenital heart defects (ASD, PDA, others)
Children with atrial septal defects or patent ductus arteriosus may require catheter-based closure or open-heart surgery if defects are large or causing heart failure or PAH.[]
The purpose is to normalise blood flow between heart chambers and lungs, which can prevent progression of pulmonary hypertension and improve growth. The mechanism is anatomical correction of shunts that overload the pulmonary circulation.
2. Orthopedic surgery for patella and limb abnormalities
Marked patellar hypoplasia, contractures, severe flat feet, or scoliosis may need surgical correction when bracing and therapy are insufficient.[]
Procedures may include tendon releases, guided growth, spinal fusion, or patella reconstruction. The goal is to improve alignment, reduce pain, and protect future mobility.
3. Gastrostomy tube placement (feeding tube)
If oral feeding remains unsafe or inadequate despite intensive support, a percutaneous endoscopic gastrostomy (PEG) may be offered.[]
This provides direct access to the stomach for nutrition and medicines, improves weight gain, and reduces aspiration. Mechanistically, it bypasses weak oral-pharyngeal swallowing without removing the possibility of continued oral feeding for pleasure.
Prevention and long-term monitoring
Because the deletion is often de novo but can sometimes be inherited, primary prevention focuses on genetic counselling and informed reproductive choices.[]
For affected individuals, “prevention” means preventing complications or detecting them early:
-
Genetic counselling for parents and relatives.
-
Early cardiac screening and follow-up to prevent advanced PAH and heart failure.
-
Regular growth and developmental assessments to trigger early therapies.
-
Hearing and vision screening to avoid avoidable developmental delay.
-
Vaccinations and infection prevention to reduce respiratory and cardiac stress.
-
Monitoring spine and limb alignment to prevent fixed contractures and scoliosis.
-
Nutritional monitoring to prevent severe under- or over-nutrition.
-
Mental health screening for anxiety, depression, or family burnout.
-
Regular review of medications for side effects, especially PAH drugs.
-
Transition planning for adolescence and adulthood, including education and employment support.
When to see a doctor urgently
Seek immediate or emergency medical care if a person with Chromosome 17q23.1-q23.2 deletion syndrome has:
-
New or worsening shortness of breath, fainting, or blue lips/skin (possible PAH or heart failure).
-
Very fast breathing or severe chest infections.
-
Poor feeding with dehydration, vomiting blood, or bile.
-
New seizures or prolonged seizure activity.
-
Sudden change in consciousness, behaviour, or severe headache.
-
Rapid worsening of scoliosis with breathing problems.
Regular, non-emergency follow-up with genetics, cardiology, pulmonology, neurology, orthopaedics, and rehab is also essential, even when the child seems stable.[]
Diet – what to eat and what to avoid
There is no special “microdeletion diet,” but nutrition should support growth, heart and lung health, and bone strength.
Helpful to include (as tolerated)
Focus on balanced meals: fruits and vegetables, whole grains, lean protein, and healthy fats. For children with heart or lung disease, dietitians may suggest higher-calorie feeds, added oils, or energy-dense oral supplements to support growth.[]
Adequate calcium, vitamin D, and protein help bones and muscles, especially if mobility is limited or steroids are used.
Important to limit or avoid (if relevant)
High-salt foods (instant noodles, salty snacks, processed meats) can worsen fluid retention in heart failure or PAH. Highly sugary drinks and ultra-processed foods may promote weight gain without good nutrition, which can further strain heart and lungs. Very large meals may worsen reflux; smaller, more frequent meals can be easier to tolerate.
All diet changes should be discussed with healthcare professionals, especially in children with complex cardiac or pulmonary disease.
Frequently asked questions (FAQs)
1. Is Chromosome 17q23.1-q23.2 deletion syndrome inherited?
Most reported cases are de novo, meaning the deletion occurred for the first time in the affected child and was not present in the parents.[]
However, sometimes a parent can carry the deletion or a related rearrangement with mild or no symptoms, so parental testing and genetic counselling are very important.
2. Is there a cure?
Currently there is no cure or gene-replacement therapy for this microdeletion. Authoritative sources emphasise that treatment focuses on managing symptoms and preventing complications through multidisciplinary care.[]
3. Will all children have severe disability?
No. The severity is very variable. Some individuals have mild learning difficulties and good function; others have more significant intellectual disability, heart or lung disease, and orthopedic problems.[]
Outcome depends on which genes are deleted, the presence of PAH or major heart defects, and the quality of early interventions.
4. How is the diagnosis confirmed?
Diagnosis is made by genetic tests such as chromosomal microarray (CMA) or next-generation sequencing-based tests that can detect microdeletions in 17q23.1-q23.2.[]
5. Can pulmonary arterial hypertension be treated effectively?
PAH in TBX4-related disease is serious but can sometimes be stabilised or improved with PAH-specific therapies (endothelin-receptor antagonists, PDE-5 inhibitors, prostacyclin analogues) and careful specialist follow-up.[]
6. Does every child with this microdeletion get PAH?
No. PAH is an important risk, especially when TBX4 is involved, but not all carriers develop it.[]
Regular cardiac and pulmonary screening is recommended when this gene region is deleted.
7. Are there research trials?
Because the condition is ultra-rare, most studies are case reports and small series, but some centres studying PAH, TBX4-related disease, or rare chromosomal disorders may offer registries or natural-history studies.[]
Families can ask genetics teams about research networks in their region.
8. What is life expectancy?
Life expectancy is not well defined due to the small number of reported cases. Outcomes depend heavily on the severity of heart and lung involvement and access to modern PAH and cardiac care.[]
9. Can adults be diagnosed later in life?
Yes. Some people with milder features, patella anomalies, or later-onset PAH may only be diagnosed in adolescence or adulthood when more detailed genetic testing is performed.[]
10. What should families remember day-to-day?
The most important points are: keep regular specialist follow-up, act early on breathing or feeding changes, support development with therapies, protect mental health, and connect with rare-disease or PAH support organisations.[]
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: January 16, 2026.
